Pluribus Labs’s ResMed RMD Stock Holding History

Pluribus Labs’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$380K	Buy	1,811 +935	+107%	+$199K	0.69%	40
2022 Q1	$212K	Buy	876 +25	+3%	+$6.05K	0.84%	40
2021 Q4	$222K	Buy	+851	New	+$221K	0.23%	195

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Pluribus Labs's RMD Position: Q2 2022 in Review

Pluribus Labs increased its ResMed (RMD) stake by 107% in Q2 2022, buying an estimated $199K and bringing the position to 1,811 shares worth $380K. The position accounts for 0.69% of the portfolio, ranked #40.

Pluribus Labs first reported a position in RMD in Q4 2021 and has held it in 3 quarters since. 676 funds tracked by Wall St. Rank hold RMD as of Q2 2022.

Pluribus Labs held 1,811 shares of ResMed worth $380K as of Q2 2022.
Pluribus Labs bought 935 ResMed shares in Q2 2022, an estimated $199K.
ResMed made up 0.69% of Pluribus Labs's portfolio in Q2 2022, its #40 holding.
Pluribus Labs first reported a position in ResMed in Q4 2021 and has held it in 3 quarters since.
676 funds tracked by Wall St. Rank held ResMed as of Q2 2022.

Based on Pluribus Labs's 13F filing for Q2 2022, filed 12 Aug 2022.